-
Product Insights
Androgenic Alopecia - Drugs In Development, 2024
Empower your strategies with our Androgenic Alopecia – Drugs In Development, 2024 report and make more profitable business decisions. Androgenic alopecia, commonly known as male-pattern baldness or female-pattern hair loss, is a hereditary condition that leads to gradual hair thinning and eventual hair loss in a specific pattern. It is the most common type of hair loss and affects both men and women, although the presentation and progression may differ between the sexes. Androgenic alopecia is primarily influenced by genetic and...
-
Sector Analysis
Androgenic Alopecia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Androgenic Alopecia Marketed and Pipeline Drugs Report Overview Androgenetic alopecia (AGA) is commonly referred to as male pattern hair loss (MPHL) or female pattern hair loss (FPHL). It is the most prevalent form of alopecia globally and is triggered by an exaggerated response to androgens. It affects at least 80% of men and 50% of women by age 70 years, with its incidence rising with age. Key Mechanisms of Action (Marketed) ·      Enzyme Inhibitor ·      Receptor Agonist ·      Receptor Antagonist...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.